Organon Shares Surge on $12 Billion Takeover Bid from Sun Pharma

Organon shares surge over 25% as Sun Pharmaceutical finalizes a $12 billion acquisition offer, triggering a fierce bidding war for the women's health specialist.

Shares of Organon & Co. skyrocketed today, propelled by reports that India's Sun Pharmaceutical Industries is finalizing a binding $12 billion acquisition offer. The potential deal, emerging after a three-month due diligence process, has ignited a fierce bidding war for the women's health specialist and sent its stock soaring by over 25% to 7.43 EUR.

The market's euphoric reaction starkly contrasts with Organon's recent financial performance. The company, spun off from Merck & Co. (MSD) in 2021, has been grappling with a significant debt burden. While management has reduced liabilities from an initial $9.5 billion to approximately $8 billion, financial pressure persists. Recent results have been lackluster: full-year 2025 revenue declined 3% to $6.2 billion, and fourth-quarter 2025 earnings per share of $0.63 missed analyst estimates, with quarterly sales falling 5.3% year-over-year to $1.51 billion.

For Sun Pharma, the move represents a strategic push to bolster its portfolio of innovative branded medicines. The Indian giant, sitting on net cash reserves of about $3.2 billion earmarked for acquisitions, is currently putting the finishing touches on its financing package for the massive bid. This aggressive posture comes despite skepticism from its own investors, who pushed Sun Pharma's stock down more than 4% on the news.

Organon is not short of suitors. At least two other global consortia are reportedly vying for the company. One group involves a buyout fund, while another is backed by a strategic investor and a European investment firm. In preparation for a potential sale of the entire business or individual divisions, Organon has already engaged Morgan Stanley as an advisor.

A takeover would accelerate Organon's ongoing strategic refocus. The company sold its JADA system for up to $465 million in January 2026, part of a plan to concentrate on its core biopharma portfolio in women's health and discontinue less profitable research programs. For the current 2026 fiscal year, leadership expects revenue to remain flat and has outlined targets to stabilize profitability, including an adjusted EBITDA of roughly $1.9 billion and a cost-saving program aiming for $275 million in reductions.

The stock's dramatic rise today has pushed it well above its 50-day moving average of 6.01 EUR and far from its recent 52-week low of 4.98 EUR. Investors now await official confirmation from the involved parties and watch for potential counterbids from rival consortia. Further clarity may arrive ahead of Organon's scheduled first-quarter 2026 results, expected to be released on Thursday, May 7, 2026.